The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Drugs are man-made miracles. They enhance our health, cure diseases, and extend our lives. However, drug development is not easy. It is a remarkably long, expensive, and complex process. On average, ...

Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and expectations from regulators, payers, and patients continue to rise. Meanwhile, ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Many clinical trials include a placebo group—participants who receive an inactive treatment—so researchers can compare ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time regulators take to review clinical trials. In a draft policy posted (Chinese ...

The new rules introduce a fast-track notification route, enabling quicker starts for lower-risk trials and maintaining safety ...

Faster Negotiations: SCs aim to significantly shorten CTA review times. Scope: The SCs cover specific terms, such as ownership of study results, publication rights, liability limitations, and ...